OKYO Pharma
OKYO
7 hedge funds and large institutions have $1.21M invested in OKYO Pharma in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.
17% more funds holding
Funds holding: 6 → 7 (+1)
0.29% more ownership
Funds ownership: 2.75% → 3.04% (+0.29%)
11% less capital invested
Capital invested by funds: $1.36M → $1.21M (-$154K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$147K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.67K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$12.9K |
| 2 |
Cerity Partners
New York
|
-$700 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Barclays
London,
United Kingdom
| $1.14M | +$147K | +105,113 | +12% |
|
2
HSBC Holdings
London,
United Kingdom
| $20.3K | – | – | – |
|
|
3
Cerity Partners
New York
| $15.2K | -$700 | -500 | -4% |
|
4
Geode Capital Management
Boston,
Massachusetts
| $14.7K | – | – | – |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $13.6K | -$12.9K | -9,187 | -45% |
|
|
6
UBS Group
Zurich,
Switzerland
| $2.27K | +$2.67K | +1,904 | New |
|
|
CA
7
Continuum Advisory
Eagle,
Idaho
| $60 | – | – | – |
|
OKYO Hedge Fund Activity: Q2 2024 in Review
7 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in OKYO Pharma (OKYO) for Q2 2024, worth a combined $1.21M — down 11% from $1.36M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new OKYO positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Barclays, adding an estimated $147K. The largest seller was Susquehanna International Group, cutting an estimated $12.9K.
- 7 institutional investors held OKYO Pharma (OKYO) as of Q2 2024, up from 6 in Q1 2024.
- Funds reported $1.21M of OKYO Pharma stock for Q2 2024, down 11% quarter-over-quarter.
- 1 fund opened new OKYO Pharma positions in Q2 2024 and 0 closed out, a net change of +1 holder.
- The largest OKYO Pharma buyer in Q2 2024 was Barclays, an estimated $147K added.
- The largest OKYO Pharma seller in Q2 2024 was Susquehanna International Group, an estimated $12.9K sold.
Based on aggregated 13F filings for Q2 2024.